APO Research
Talk to an analyst

APO RESEARCH · REPORT

Veterinary Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Veterinary Therapeutics Market Outlook and Growth Opportunities 2026

21 December 2025201 pages

Choose your research edition.

Industry ResearchVeterinary Therapeutics Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Veterinary Therapeutics Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Veterinary Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Veterinary Therapeutics Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Veterinary Therapeutics Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Veterinary Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Veterinary Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Veterinary Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Veterinary Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Veterinary Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Veterinary Therapeutics market include CAHIC, Zoetis, Ringpu Biology, Merck, Virbac, Vetoquinol, Phibro, Ouro Fino Saude and Orion, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Veterinary Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Veterinary Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Veterinary Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Veterinary Therapeutics market.

Veterinary Therapeutics Segment by Company

CAHIC

Zoetis

Ringpu Biology

Merck

Virbac

Vetoquinol

Phibro

Ouro Fino Saude

Orion

Norbrook

Nippon Zenyaku Kogyo

Huvepharma

Hipra

Farmavet-Pasteur

Elanco

Dechra

Ceva

Boehringer Ingelheim

Veterinary Therapeutics Segment by Type

Analgesics

Sedatives

Anti-Inflammatory

Parasiticides

Anti-Infectives

Others

Veterinary Therapeutics Segment by Application

Swine

Cattle

Poultry

Pets

Others

Veterinary Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Veterinary Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Veterinary Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Veterinary Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Veterinary Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Veterinary Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Veterinary Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Veterinary Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Veterinary Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Veterinary Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Veterinary Therapeutics industry.

Chapter 3: Detailed analysis of Veterinary Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Veterinary Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Veterinary Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Veterinary Therapeutics Industry Trends Table 2. Veterinary Therapeutics Industry Drivers Table 3. Veterinary Therapeutics Industry Opportunities and Challenges Table 4. Veterinary Therapeutics Industry Restraints Table 5. Global Veterinary Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Veterinary Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Veterinary Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Veterinary Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Veterinary Therapeutics Company, Product Type & Application Table 10. Global Veterinary Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Veterinary Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Analgesics Table 15. Significant Companies of Sedatives Table 16. Significant Companies of Anti-Inflammatory Table 17. Significant Companies of Parasiticides Table 18. Significant Companies of Anti-Infectives Table 19. Significant Companies of Others Table 20. Global Veterinary Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Veterinary Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Veterinary Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Veterinary Therapeutics Sales Value Share by Type (2021-2026) Table 24. Global Veterinary Therapeutics Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Swine Table 26. Significant Companies of Cattle Table 27. Significant Companies of Poultry Table 28. Significant Companies of Pets Table 29. Significant Companies of Others Table 30. Global Veterinary Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Veterinary Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 32. Global Veterinary Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 33. Global Veterinary Therapeutics Sales Value Share by Application (2021-2026) Table 34. Global Veterinary Therapeutics Sales Value Share by Application (2027-2032) Table 35. Global Veterinary Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Veterinary Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 37. Global Veterinary Therapeutics Sales Value Share by Region (2021-2026) Table 38. Global Veterinary Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 39. Global Veterinary Therapeutics Sales Value Share by Region (2027-2032) Table 40. Global Veterinary Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Veterinary Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 42. Global Veterinary Therapeutics Sales Value Market Share by Country (2021-2026) Table 43. Global Veterinary Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 44. Global Veterinary Therapeutics Sales Value Market Share by Country (2027-2032) Table 45. CAHIC Company Information Table 46. CAHIC Business Overview Table 47. CAHIC Veterinary Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. CAHIC Veterinary Therapeutics Product Portfolio Table 49. CAHIC Recent Development Table 50. Zoetis Company Information Table 51. Zoetis Business Overview Table 52. Zoetis Veterinary Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Zoetis Veterinary Therapeutics Product Portfolio Table 54. Zoetis Recent Development Table 55. Ringpu Biology Company Information Table 56. Ringpu Biology Business Overview Table 57. Ringpu Biology Veterinary Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Ringpu Biology Veterinary Therapeutics Product Portfolio Table 59. Ringpu Biology Recent Development Table 60. Merck Company Information Table 61. Merck Business Overview Table 62. Merck Veterinary Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Merck Veterinary Therapeutics Product Portfolio Table 64. Merck Recent Development Table 65. Virbac Company Information Table 66. Virbac Business Overview Table 67. Virbac Veterinary Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Virbac Veterinary Therapeutics Product Portfolio Table 69. Virbac Recent Development Table 70. Vetoquinol Company Information Table 71. Vetoquinol Business Overview Table 72. Vetoquinol Veterinary Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Vetoquinol Veterinary Therapeutics Product Portfolio Table 74. Vetoquinol Recent Development Table 75. Phibro Company Information Table 76. Phibro Business Overview Table 77. Phibro Veterinary Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Phibro Veterinary Therapeutics Product Portfolio Table 79. Phibro Recent Development Table 80. Ouro Fino Saude Company Information Table 81. Ouro Fino Saude Business Overview Table 82. Ouro Fino Saude Veterinary Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Ouro Fino Saude Veterinary Therapeutics Product Portfolio Table 84. Ouro Fino Saude Recent Development Table 85. Orion Company Information Table 86. Orion Business Overview Table 87. Orion Veterinary Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Orion Veterinary Therapeutics Product Portfolio Table 89. Orion Recent Development Table 90. Norbrook Company Information Table 91. Norbrook Business Overview Table 92. Norbrook Veterinary Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Norbrook Veterinary Therapeutics Product Portfolio Table 94. Norbrook Recent Development Table 95. Nippon Zenyaku Kogyo Company Information Table 96. Nippon Zenyaku Kogyo Business Overview Table 97. Nippon Zenyaku Kogyo Veterinary Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Nippon Zenyaku Kogyo Veterinary Therapeutics Product Portfolio Table 99. Nippon Zenyaku Kogyo Recent Development Table 100. Huvepharma Company Information Table 101. Huvepharma Business Overview Table 102. Huvepharma Veterinary Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Huvepharma Veterinary Therapeutics Product Portfolio Table 104. Huvepharma Recent Development Table 105. Hipra Company Information Table 106. Hipra Business Overview Table 107. Hipra Veterinary Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Hipra Veterinary Therapeutics Product Portfolio Table 109. Hipra Recent Development Table 110. Farmavet-Pasteur Company Information Table 111. Farmavet-Pasteur Business Overview Table 112. Farmavet-Pasteur Veterinary Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Farmavet-Pasteur Veterinary Therapeutics Product Portfolio Table 114. Farmavet-Pasteur Recent Development Table 115. Elanco Company Information Table 116. Elanco Business Overview Table 117. Elanco Veterinary Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Elanco Veterinary Therapeutics Product Portfolio Table 119. Elanco Recent Development Table 120. Dechra Company Information Table 121. Dechra Business Overview Table 122. Dechra Veterinary Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 123. Dechra Veterinary Therapeutics Product Portfolio Table 124. Dechra Recent Development Table 125. Ceva Company Information Table 126. Ceva Business Overview Table 127. Ceva Veterinary Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 128. Ceva Veterinary Therapeutics Product Portfolio Table 129. Ceva Recent Development Table 130. Boehringer Ingelheim Company Information Table 131. Boehringer Ingelheim Business Overview Table 132. Boehringer Ingelheim Veterinary Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 133. Boehringer Ingelheim Veterinary Therapeutics Product Portfolio Table 134. Boehringer Ingelheim Recent Development Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Veterinary Therapeutics Product Image Figure 2. Global Veterinary Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Veterinary Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Veterinary Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Analgesics Image Figure 8. Sedatives Image Figure 9. Anti-Inflammatory Image Figure 10. Parasiticides Image Figure 11. Anti-Infectives Image Figure 12. Others Image Figure 13. Global Veterinary Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Veterinary Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Veterinary Therapeutics Sales Value Share by Type (2021-2032) Figure 16. Swine Image Figure 17. Cattle Image Figure 18. Poultry Image Figure 19. Pets Image Figure 20. Others Image Figure 21. Global Veterinary Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Veterinary Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 23. Global Veterinary Therapeutics Sales Value Share by Application (2021-2032) Figure 24. Global Veterinary Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 25. Global Veterinary Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 26. North America Veterinary Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 27. North America Veterinary Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Europe Veterinary Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 29. Europe Veterinary Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Asia-Pacific Veterinary Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 31. Asia-Pacific Veterinary Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 32. South America Veterinary Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 33. South America Veterinary Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Middle East & Africa Veterinary Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 35. Middle East & Africa Veterinary Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 36. USA Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. USA Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. USA Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Canada Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Canada Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Canada Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Mexico Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Mexico Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Mexico Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Germany Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Germany Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Germany Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. France Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. France Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. France Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. U.K. Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. U.K. Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. U.K. Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Italy Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Italy Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Italy Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Spain Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Spain Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Spain Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Russia Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Russia Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Russia Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Netherlands Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Netherlands Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Netherlands Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Nordic Countries Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Nordic Countries Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Nordic Countries Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. China Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. China Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. China Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Japan Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Japan Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Japan Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. South Korea Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. South Korea Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. South Korea Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. India Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. India Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. India Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Australia Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Australia Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Australia Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Southeast Asia Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Southeast Asia Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Southeast Asia Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Brazil Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Brazil Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Brazil Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Argentina Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Argentina Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Argentina Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Chile Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Chile Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Chile Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Colombia Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Colombia Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Colombia Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Peru Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Peru Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Peru Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Saudi Arabia Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Saudi Arabia Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Israel Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Israel Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Israel Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. UAE Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. UAE Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. UAE Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Turkey Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Turkey Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Turkey Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Iran Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Iran Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Iran Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Egypt Veterinary Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Egypt Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Egypt Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Years Considered Figure 121. Research Process Figure 122. Key Executives Interviewed

Scope & coverage.

Types
  • Analgesics
  • Sedatives
  • Anti-Inflammatory
  • Parasiticides
  • Anti-Infectives
  • Others
Applications
  • Swine
  • Cattle
  • Poultry
  • Pets
  • Others
Companies covered
  • CAHIC
  • Zoetis
  • Ringpu Biology
  • Merck
  • Virbac
  • Vetoquinol
  • Phibro
  • Ouro Fino Saude
  • Orion
  • Norbrook
  • Nippon Zenyaku Kogyo
  • Huvepharma
  • Hipra
  • Farmavet-Pasteur
  • Elanco
  • Dechra
  • Ceva
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Veterinary Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Veterinary Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Veterinary Therapeutics Market Dynamics
  1. 2.1 Veterinary Therapeutics Industry Trends
  2. 2.2 Veterinary Therapeutics Industry Drivers
  3. 2.3 Veterinary Therapeutics Industry Opportunities and Challenges
  4. 2.4 Veterinary Therapeutics Industry Restraints
3 Veterinary Therapeutics Market by Company
  1. 3.1 Global Veterinary Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Veterinary Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Veterinary Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Veterinary Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Veterinary Therapeutics Company Product Type and Application
  6. 3.6 Global Veterinary Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Veterinary Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Veterinary Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Veterinary Therapeutics Market by Type
  1. 4.1 Veterinary Therapeutics Type Introduction
  2. 4.1.1 Analgesics
  3. 4.1.2 Sedatives
  4. 4.1.3 Anti-Inflammatory
  5. 4.1.4 Parasiticides
  6. 4.1.5 Anti-Infectives
  7. 4.1.6 Others
  8. 4.2 Global Veterinary Therapeutics Sales Value by Type
  9. 4.2.1 Global Veterinary Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Veterinary Therapeutics Sales Value by Type (2021-2032)
  11. 4.2.3 Global Veterinary Therapeutics Sales Value Share by Type (2021-2032)
5 Veterinary Therapeutics Market by Application
  1. 5.1 Veterinary Therapeutics Application Introduction
  2. 5.1.1 Swine
  3. 5.1.2 Cattle
  4. 5.1.3 Poultry
  5. 5.1.4 Pets
  6. 5.1.5 Others
  7. 5.2 Global Veterinary Therapeutics Sales Value by Application
  8. 5.2.1 Global Veterinary Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Veterinary Therapeutics Sales Value by Application (2021-2032)
  10. 5.2.3 Global Veterinary Therapeutics Sales Value Share by Application (2021-2032)
6 Veterinary Therapeutics Regional Value Analysis
  1. 6.1 Global Veterinary Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Veterinary Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Veterinary Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Veterinary Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Veterinary Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Veterinary Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Veterinary Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Veterinary Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Veterinary Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Veterinary Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Veterinary Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Veterinary Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Veterinary Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Veterinary Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Veterinary Therapeutics Country-level Value Analysis
  1. 7.1 Global Veterinary Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Veterinary Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Veterinary Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Veterinary Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Veterinary Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Veterinary Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Veterinary Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CAHIC
  2. 8.1.1 CAHIC Company Information
  3. 8.1.2 CAHIC Business Overview
  4. 8.1.3 CAHIC Veterinary Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 CAHIC Veterinary Therapeutics Product Portfolio
  6. 8.1.5 CAHIC Recent Developments
  7. 8.2 Zoetis
  8. 8.2.1 Zoetis Company Information
  9. 8.2.2 Zoetis Business Overview
  10. 8.2.3 Zoetis Veterinary Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Zoetis Veterinary Therapeutics Product Portfolio
  12. 8.2.5 Zoetis Recent Developments
  13. 8.3 Ringpu Biology
  14. 8.3.1 Ringpu Biology Company Information
  15. 8.3.2 Ringpu Biology Business Overview
  16. 8.3.3 Ringpu Biology Veterinary Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Ringpu Biology Veterinary Therapeutics Product Portfolio
  18. 8.3.5 Ringpu Biology Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Veterinary Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck Veterinary Therapeutics Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Virbac
  26. 8.5.1 Virbac Company Information
  27. 8.5.2 Virbac Business Overview
  28. 8.5.3 Virbac Veterinary Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Virbac Veterinary Therapeutics Product Portfolio
  30. 8.5.5 Virbac Recent Developments
  31. 8.6 Vetoquinol
  32. 8.6.1 Vetoquinol Company Information
  33. 8.6.2 Vetoquinol Business Overview
  34. 8.6.3 Vetoquinol Veterinary Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Vetoquinol Veterinary Therapeutics Product Portfolio
  36. 8.6.5 Vetoquinol Recent Developments
  37. 8.7 Phibro
  38. 8.7.1 Phibro Company Information
  39. 8.7.2 Phibro Business Overview
  40. 8.7.3 Phibro Veterinary Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Phibro Veterinary Therapeutics Product Portfolio
  42. 8.7.5 Phibro Recent Developments
  43. 8.8 Ouro Fino Saude
  44. 8.8.1 Ouro Fino Saude Company Information
  45. 8.8.2 Ouro Fino Saude Business Overview
  46. 8.8.3 Ouro Fino Saude Veterinary Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Ouro Fino Saude Veterinary Therapeutics Product Portfolio
  48. 8.8.5 Ouro Fino Saude Recent Developments
  49. 8.9 Orion
  50. 8.9.1 Orion Company Information
  51. 8.9.2 Orion Business Overview
  52. 8.9.3 Orion Veterinary Therapeutics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Orion Veterinary Therapeutics Product Portfolio
  54. 8.9.5 Orion Recent Developments
  55. 8.10 Norbrook
  56. 8.10.1 Norbrook Company Information
  57. 8.10.2 Norbrook Business Overview
  58. 8.10.3 Norbrook Veterinary Therapeutics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Norbrook Veterinary Therapeutics Product Portfolio
  60. 8.10.5 Norbrook Recent Developments
  61. 8.11 Nippon Zenyaku Kogyo
  62. 8.11.1 Nippon Zenyaku Kogyo Company Information
  63. 8.11.2 Nippon Zenyaku Kogyo Business Overview
  64. 8.11.3 Nippon Zenyaku Kogyo Veterinary Therapeutics Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Nippon Zenyaku Kogyo Veterinary Therapeutics Product Portfolio
  66. 8.11.5 Nippon Zenyaku Kogyo Recent Developments
  67. 8.12 Huvepharma
  68. 8.12.1 Huvepharma Company Information
  69. 8.12.2 Huvepharma Business Overview
  70. 8.12.3 Huvepharma Veterinary Therapeutics Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Huvepharma Veterinary Therapeutics Product Portfolio
  72. 8.12.5 Huvepharma Recent Developments
  73. 8.13 Hipra
  74. 8.13.1 Hipra Company Information
  75. 8.13.2 Hipra Business Overview
  76. 8.13.3 Hipra Veterinary Therapeutics Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Hipra Veterinary Therapeutics Product Portfolio
  78. 8.13.5 Hipra Recent Developments
  79. 8.14 Farmavet-Pasteur
  80. 8.14.1 Farmavet-Pasteur Company Information
  81. 8.14.2 Farmavet-Pasteur Business Overview
  82. 8.14.3 Farmavet-Pasteur Veterinary Therapeutics Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Farmavet-Pasteur Veterinary Therapeutics Product Portfolio
  84. 8.14.5 Farmavet-Pasteur Recent Developments
  85. 8.15 Elanco
  86. 8.15.1 Elanco Company Information
  87. 8.15.2 Elanco Business Overview
  88. 8.15.3 Elanco Veterinary Therapeutics Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Elanco Veterinary Therapeutics Product Portfolio
  90. 8.15.5 Elanco Recent Developments
  91. 8.16 Dechra
  92. 8.16.1 Dechra Company Information
  93. 8.16.2 Dechra Business Overview
  94. 8.16.3 Dechra Veterinary Therapeutics Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Dechra Veterinary Therapeutics Product Portfolio
  96. 8.16.5 Dechra Recent Developments
  97. 8.17 Ceva
  98. 8.17.1 Ceva Company Information
  99. 8.17.2 Ceva Business Overview
  100. 8.17.3 Ceva Veterinary Therapeutics Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Ceva Veterinary Therapeutics Product Portfolio
  102. 8.17.5 Ceva Recent Developments
  103. 8.18 Boehringer Ingelheim
  104. 8.18.1 Boehringer Ingelheim Company Information
  105. 8.18.2 Boehringer Ingelheim Business Overview
  106. 8.18.3 Boehringer Ingelheim Veterinary Therapeutics Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Boehringer Ingelheim Veterinary Therapeutics Product Portfolio
  108. 8.18.5 Boehringer Ingelheim Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst